
Overview
Novartis Poland is part of a global healthcare company that works with patients, caregivers and healthcare professionals to improve and extend human life. The company supports knowledge exchange, education and therapy development, while pursuing environmental and social responsibility and building a diverse team serving more than 766 million patients worldwide.
Financials
Revenue history (in m)
From the notes
| Current income tax (CIT due) | $3,001,733 |
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 69 days for 2021). All were audited by a statutory auditor.
- 202525/08/2026
- 202403/07/2025
- 202305/07/2024
- 202212/07/2023
- 202122/09/2022
- 202006/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News
Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term
Ad hoc announcement pursuant to Art. 53 LR
Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS
Basel, November 18, 2026 – Novartis will present data from nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS) and 68ᵗʰ American Society of Hematology (ASH) Annual Meeting & Exposition. Together, the data reinforce Novartis leadership in breast cancer and hematology, spanning approved medicines and a promising pipeline of next-generation therapies.
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing…
Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)
Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx ® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy. 6 If approved by the European Commission (EC), Cosentyx would become the…
New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)
Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU). 1 The data will be presented as a…
Novartis ranks first place in 2026 Access to Medicine Index
Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines. “Being ranked first in the Access to Medicine Index for the second consecutive time is an honor, and a recognition of our continued efforts to expand access to healthcare together with our partners,” said Vas Narasimhan…
Industry
- Publishing of books, periodicals and other publishing activities, excluding software (58.1)
Offer
- Oncology medicines
- Neurology medicines
- Ophthalmic medicines
Websites
The company has 5 websites, including 2 versions for foreign markets (e.g. China, Russia). Most of them run on Drupal. The sites are available in: English, Russian and Chinese.
- novartis.comNovartisDrupalGoogle Tag ManagerCloudflare
- zaawansowanyrakpiersi.plZaawansowany rak piersi – pomoc | Portal informacyjnyWordPress 3.7Google Tag ManagerYoast SEOLLiteSpeed
- novartis.com.cn诺华集团中文官方网站DrupalCloudflare
Public procurement
13 tenders recorded as contractor, with a total value of $34,796,045.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Nov 13, 2026 | Supply of medicinal products, pharmaceutical preparations, medical devices and other products | $3.7M$3,710,859 | Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza w Bydgoszczy | |
| Feb 24, 2026 | Supply of medicinal products for drug programmes as part of CAR-T therapy | $1.7M$1,717,990 | Uniwersytecki Szpital Kliniczny w Poznaniu | |
| Oct 1, 2025 | Supply of medicines, pharmaceutical preparations, oncology medicines, medical devices, dressings, sutures, contrast agents and other items. | $2.6M$2,555,500 | Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza w Bydgoszczy |
The company is the contractor in 8 public sector contracts, worth USD 4.12m in total. They were signed with 6 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Oct 29, 2026 | Tisagenlecleucel | $3,435,981 | Szpital Uniwersytecki Nr 1 Im. Dr. A. Jurasza w Bydgoszczy | |
| Oct 13, 2026 | Medicinal products | $0.81 | Centrum Onkologii Im. Prof. Franciszka Łukaszczyka w Bydgoszczy | |
| Aug 28, 2026 | Tisagenlecleucel. | $687,196 | Uniwersyteckie Centrum Kliniczne |
Trademarks
The company currently holds no active trademarks with the Polish Patent Office. 3 marks have expired or were not registered. The first mark was filed in 2009.
| Mark | Protected until | |
|---|---|---|
| ZROZUM LEPIEJ SWOJĄ MIGRENĘ Z EXCEDRIN MIGRASTOP | – | |
| DiabetoNews (word) | – | |
| KOJĄCY DOTYK (word) | – |
Job offers
The company has its own careers page: novartis.com/careers.
Authorized Representatives
Manner of representation
The following are authorized to submit declarations of will within the scope of rights and obligations and to sign documents on behalf of the company: each member of the management board independently or an individual commercial proxy independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Novartis Pharma Ag | 44,183 | $11,934,900.05 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the Novartis AG (Switzerland) group. Its direct owner is Novartis Pharma AG (Switzerland). The group has 17 companies, 15 of them abroad.
| Name | Country |
|---|---|
| Alcon Ophthalmika GmbH | |
| EBEWE Pharma Ges.m.b.H. Nfg.KG | |
| Evonile Pharma Limited | |
| Novartis Bioventures AG | |
| Novartis Capital Corporation |
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 1993-07-05.
29 1600 1462 1847 1458 5000 0027
85 1600 1127 1847 1458 5000 0001
31 1600 1127 1847 1458 5000 0003
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 1.6MPLN 1,584,787 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Apr 22, 2025 | Merger registered |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Novo Nordisk Pharmaceutical Services sp. z o.o. | $405,739,463.75 | novonordisk.pl | ||
| MSD Polska Dystrybucja sp. z o.o. | $341,786,056.16 | msd.pl | ||
| Janssen-Cilag Polska sp. z o.o. | $323,933,929.12 | janssen.pl | ||
| Bristol-Myers Squibb Polska sp. z o.o. | $230,722,737.87 | bms.com | ||
| Astellas Pharma sp. z o.o. | $220,199,081.58 | astellas.com | ||
| Accord Healthcare Polska sp. z o.o. | $178,502,388.11 | accord-healthcare.pl | ||
| Gilead Sciences Poland sp. z o.o. | $150,844,944.19 | gilead.com | ||
| Amgen sp. z o.o. | $145,068,009.51 | amgen.pl | ||
| Pfizer Polska sp. z o.o. | $110,632,345.55 | pfizer.pl | ||
| Ipsen Poland sp. z o.o. | $94,814,847.87 | ipsen.com |
Change history
| Date | Event | |
|---|---|---|
| 2010-12-20 | Address change (Al.wincentego Witosa 31, 00-710, Warszawa → Marynarska 15, 02-674, Warszawa) | |
| 2004-02-16 | Share capital increase (44,182,900.00 PLN → 44,183,000.00 PLN) | |
| 2001-10-31 | Entered in the register |
FAQ
Last updated: 2026-10-02